Table 1.

Patient demographics on the day of study

DemographicsAll Patients (n = 49)No LVH (n = 25)LVH (n = 24)P
Age (years)12.6 ± 3.013.0 ± 3.012.3 ± 3.10.41
Male gender, n (%)29 (59.2%)13 (52%)16 (66.7%)0.39
Primary diagnosis structural disease, n (%)38 (77.6%)21 (84%)17 (70.8%)0.32
Height z-score−0.65 ± 1.28−0.69 ± 1.34−0.62 ± 1.230.84
Weight z-score0.03 ± 1.26−0.25 ± 1.210.33 ± 1.270.10
BMI z-score0.53 ± 1.290.18 ± 1.330.89 ± 1.170.05
Antihypertensive medications, n (%)27 (55.1%)13 (52%)14 (58.3%)0.78
ACEI ± ARB or combination with ACEI ± ARB, n241311
CKD stage 3; stage 4; stage 5, n19; 22; 811; 11; 38; 11; 50.64
Hydroxylated vitamin D3, n3516190.61
Hydroxylated vitamin D3 dose, μg/d0.41 ± 0.230.39 ± 0.220.43 ± 0.25
  • Data shown as mean ± SD unless stated otherwise. LVH was defined using age-specific reference intervals for normal children (19). ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker.